PFIZER IS BUILDING ONTO THE CLINICAL EXPERIENCE OF PEGFILGRASTIM

​​​​​​NYVEPRIA is an FDA-approved biosimilar to Neulasta® (pegfilgrastim)1*

​​​​​​Access & Support

Making your patients’ support needs a priority. Together.

At Pfizer Oncology Together, patient support is at the core of everything we do. From helping to identify financial support options for eligible patients, to connecting patients to resources for emotional support, your patients’ needs are our priority.

FOR LIVE, PERSONALIZED SUPPORT

Call 1-877-744-5675 (Monday-Friday 8 AM - 8 PM ET)

Visit Pfizer Oncology Together


​​​​​​​Finding financial support options. Together.

Commercially Insured

Resources for eligible commercial, private, employer, and state health insurance marketplace patients: The Pfizer Oncology Together Co-Pay Savings Program for Injectables provides eligible, commercially insured patients prescribed NYVEPRIA with support for out-of-pocket drug costs, including co-pays and coinsurance. Limits, terms, and conditions apply. See below.

For eligible, commercially insured patients
Eligible patients may pay as little as $0 for each NYVEPRIA treatment.

Up to $10,000 per calendar year
The program covers up to $10,000 per calendar year.

No income requirements
There are no income requirements for patients to qualify.

Medicare/Government Insured

Help identifying resources for eligible patients with Medicare, Medicaid, and other government insurance plans:

  • Assistance with searching for financial support that may be available from independent charitable foundations. These foundations exist independently of Pfizer and have their own eligibility criteria and application processes. Availability of support from the foundations is determined solely by the foundations
  • Free medication

Uninsured

Help identifying resources for eligible patients without any form of healthcare coverage:

  • Help finding coverage
  • Free medication through the Pfizer Patient Assistance Program


​​​​​​​Tailoring support to patients’ daily needs. Together.

When your patients need support for their day-to-day challenges, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed our medications to resources that may help with some of their daily needs§:

  • Connections to emotional support resources
  • Connections to an independent organization that helps eligible patients find rides and lodging for treatment-related appointments
  • Educational information on topics such as nutrition
  • Information to help patients prepare for leaving or returning to work
  • Help identifying financial assistance resources


​​​​​​​Navigating access and reimbursement. Together.

If patients need access or reimbursement support, Pfizer Oncology Together is here to help.

Benefits Verification

We can help determine a patient’s coverage and out-of-pocket costs.

Prior Authorizations (PA)

We can coordinate with a patient’s insurer to determine the PA requirements. After a PA request is submitted, we can follow up with the payer until a final outcome is determined.

Appeals Assistance

We can review the reasons for a denied claim and provide information on payer requirements. After an appeal is submitted, we can follow up with the payer until a final outcome is determined.

Product Distribution Information

NYVEPRIA is available through most major wholesalers.

Billing and Coding Assistance for Injectable Products

For your patient claim submissions, we provide easy access to sample forms and template letters, along with billing and coding information for physician’s office and hospital outpatient settings of care.

Dedicated Local Support

Pfizer Oncology Account Specialists can provide detailed information on Pfizer Oncology medications and access resources. In addition, they can help you and your office staff contact a Pfizer Oncology Field Reimbursement Manager (FRM) in your area.

FRMs are trained to help address specific access issues—in person or over the phone. They can help educate your staff on our access and reimbursement resources and help address challenging or urgent Pfizer Oncology patient cases you have sent to Pfizer Oncology Together.
​​​​​​​

   *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1
​​​​​​​​​​​​​

   †Terms and Conditions
​​​​​​​
By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms and Conditions described below:
​​​​​​​

  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance. Offer is not valid for cash-paying patients.
  • With this card, eligible patients will pay a $0 co-pay per eligible monthly prescription, subject to a maximum amount of $10,000 per calendar year. The amount of any benefit is the difference between your co-pay and $0. After the annual maximum of $10,000 is reached, you will be responsible for the remaining monthly out-of-pocket costs. This card may not be redeemed more than once per 30 days.
  • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required.
  • You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
  • This co-pay card is not valid where prohibited by law.
  • Card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
  • Card will be accepted only at participating pharmacies.
  • This card is not health insurance.
  • Offer good only in the U.S. and Puerto Rico. Card is limited to 1 per person during this offering period and is not transferable.
  • No other purchase is necessary
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  • Offer expires 12/31/2021.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
  • Mail a copy of the patient’s pharmacy receipt indicating patient name, name of medication purchased, price paid, and date purchased, along with a copy of the patient’s Pfizer Oncology Together Co-Pay Savings Card, to:
    ​​​​​​​​​​​​​​
    Pfizer Oncology Together Co-Pay Savings Program
    2250 Perimeter Park Drive, Suite 300
    ​​​​​​​Morrisville, NC 27560

   If support from independent charitable foundations is not available, Pfizer Oncology Together will provide eligible patients with medication for free through the Pfizer Patient Assistance Program. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

   §Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

Support & Resources

Access & Support
  • Downloadable Resources
  • References

NYVEPRIA PD/PK data supports no clinically meaningful differences in efficacy vs Neulasta2

Studies in support of biosimilarity in healthy volunteers

Review clinical data

** This is an optional area where footnotes can live.

NYVEPRIA had a comparable safety profile vs Neulasta across adverse event categories2

Studies in support of biosimilarity in healthy volunteers

Review safety data

** This is an optional area where footnotes can live.

Contraindications
  • NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
  • Reactions have included anaphylaxis
Warnings and Precautions
Splenic Rupture
  • Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
  • Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA
Acute Respiratory Distress Syndrome (ARDS)
  • ARDS can occur in patients receiving pegfilgrastim products
  • Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
  • Discontinue NYVEPRIA in patients with ARDS
Serious Allergic Reactions
  • Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
  • The majority of reported events occurred upon initial exposure
  • Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti‐allergic treatment
  • Permanently discontinue NYVEPRIA in patients with serious allergic reactions
  • Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
Use in Patients with Sickle Cell Disorders
  • Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
  • Discontinue NYVEPRIA if sickle cell crisis occurs
Glomerulonephritis
  • Glomerulonephritis has occurred in patients receiving pegfilgrastim products
  • The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
  • Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
  • If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA
Leukocytosis
  • White blood cell counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim products
  • Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended
Thrombocytopenia
  • Thrombocytopenia has been reported in patients receiving pegfilgrastim products
  • Monitor platelet counts
Capillary Leak Syndrome (CLS)
  • CLS has been reported after granulocyte-colony stimulating factor (G‐CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency and severity and may be life‐threatening if treatment is delayed
  • Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
  • The G-CSF receptor through which pegfilgrastim and filgrastim products act has been found on tumor cell lines
  • The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer
  • MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer
  • Monitor patients for signs and symptoms of MDS/AML in these settings
Aortitis
  • Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NYVEPRIA if aortitis is suspected
Nuclear Imaging
  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results
Most Common Adverse Reactions
  • Bone pain
  • Pain in extremity

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.

Indication

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

 
Limitations of Use
 

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.